| Autor: |
Sinha, Neelima, Karche, Navnath P., Verma, Mahip Kalyan, Walunj, Sameer S., Nigade, Prashant B., Jana, Gourhari, Kurhade, Sanjay P., Hajare, Anil K., Tilekar, Ajay R., Jadhav, Ganesh R., Thube, Baban R., Shaikh, Javed S., Balgude, Sudhakar, Singh, Lairikyengbam Bikramjit, Mahimane, Vijaya, Adurkar, Shridhar K., Hatnapure, Girish, Raje, Firoj, Bhosale, Yogesh, Bhanage, Dnyaneshwar, Sachchidanand, Sachchidanand, Dixit, Ruchi, Gupta, Rajesh, Bokare, Anand M., Dandekar, Manoj, Bharne, Ashish, Chatterjee, Manavi, Desai, Sagar, Koul, Sarita, Modi, Dipak, Mehta, Maneesh, Patil, Vinod, Singh, Minakshi, Gundu, Jayasagar, Goel, Rajan N., Shah, Chirag, Sharma, Sharad, Bakhle, Dhananjay, Kamboj, Rajender Kumar, Palle, Venkata P. |
| Zdroj: |
Journal of Medicinal Chemistry; February 2020, Vol. 63 Issue: 3 p944-960, 17p |
| Abstrakt: |
The discovery of a series of thiophenephenylsulfonamides as positive allosteric modulators (PAM) of α7 nicotinic acetylcholine receptor (α7 nAChR) is described. Optimization of this series led to identification of compound 28,a novel PAM of α7 nicotinic acetylcholine receptor (α7 nAChR). Compound 28showed good in vitro potency, with pharmacokinetic profile across species with excellent brain penetration and residence time. Compound 28robustly reversed the cognitive deficits in episodic/working memory in both time-delay and scopolamine-induced amnesia paradigms in the novel object and social recognition tasks, at very low dose levels. Additionally, compound 28has shown excellent safety profile in phase 1 clinical trials and is being evaluated for efficacy and safety as monotherapy in patients with mild to moderate Alzheimer’s disease. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
